Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 ... MarketWatch (press release) The title of the DSHNHL study is "Improvement of outcome and reduction in toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimized schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal ... |
